Baird raised the firm’s price target on Agenus (AGEN) to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- Strategic Collaboration Between Agenus and Zydus Lifesciences Boosts Financial Position and Product Development
- Agenus upgraded to Buy from Neutral at H.C. Wainwright
- Agenus selling U.S. manufacturing facilities to Zydus
- Agenus, Zydus enter $141M collaboration for BOT/BAL production orders
- Agenus presents new translational data at 2025 ASCO meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue